XELJANZ 11 mg prolonged-release tablets

DRUG3 trials

Sponsors

Universitaetsklinikum Erlangen AöR, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Sint Maartenskliniek Stichting

Conditions

Psoriatic arthritisRheumatoid arthritisRheumatoid arthritis or psoriatic arthritis according to respectively 2010 criteria or CASPAR criteriapsoriatic arthritis and axial spondyloarthritis

Phase 3

A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis

RecruitingCTIS2023-508251-39-00

Universitaetsklinikum Erlangen AöRPsoriatic arthritis

Start: 2020-09-18Target: 370Updated: 2026-01-20

Phase 4

Chronotherapy in Inflammatory Arthritis (ChronIA trial): a randomized controlled trial comparing the effectiveness of morning and evening dosing of tofacitinib extended-release

Not yet recruitingCTIS2024-517865-17-01

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rheumatoid arthritis or psoriatic arthritis according to respectively 2010 criteria or CASPAR criteria

Target: 84Updated: 2024-09-30

REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases

RecruitingCTIS2025-520757-36-00

Sint Maartenskliniek Stichtingpsoriatic arthritis and axial spondyloarthritis, Rheumatoid arthritis

Start: 2025-09-15Target: 200Updated: 2026-01-13